WO2017188684A1 - 코리네박테리움 글루타미쿰을 이용한 2'-푸코실락토오스의 생산방법 - Google Patents
코리네박테리움 글루타미쿰을 이용한 2'-푸코실락토오스의 생산방법 Download PDFInfo
- Publication number
- WO2017188684A1 WO2017188684A1 PCT/KR2017/004340 KR2017004340W WO2017188684A1 WO 2017188684 A1 WO2017188684 A1 WO 2017188684A1 KR 2017004340 W KR2017004340 W KR 2017004340W WO 2017188684 A1 WO2017188684 A1 WO 2017188684A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fucosyllactose
- corynebacterium glutamicum
- glutamicum
- lactose
- mannose
- Prior art date
Links
- 241000186226 Corynebacterium glutamicum Species 0.000 title claims abstract description 94
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 title claims abstract description 79
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 title claims abstract description 79
- 229940062827 2'-fucosyllactose Drugs 0.000 title claims abstract description 78
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 title claims abstract description 78
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 49
- 108010060845 lactose permease Proteins 0.000 claims abstract description 15
- RTVRUWIBAVHRQX-PMEZUWKYSA-N Fucosyllactose Chemical compound C([C@H]1O[C@@H]([C@H]([C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H]1O)O)OC)O[C@H]1OC[C@@H](O)[C@H](O)[C@@H]1O RTVRUWIBAVHRQX-PMEZUWKYSA-N 0.000 claims abstract description 10
- 108010062427 GDP-mannose 4,6-dehydratase Proteins 0.000 claims abstract description 10
- 102000002312 GDPmannose 4,6-dehydratase Human genes 0.000 claims abstract description 10
- 101710098620 Alpha-1,2-fucosyltransferase Proteins 0.000 claims abstract description 9
- 102100024515 GDP-L-fucose synthase Human genes 0.000 claims abstract description 9
- 108030006298 GDP-L-fucose synthases Proteins 0.000 claims abstract description 8
- 108010038016 Mannose-1-phosphate guanylyltransferase Proteins 0.000 claims abstract description 7
- 102000030605 Phosphomannomutase Human genes 0.000 claims abstract description 7
- 108091000115 phosphomannomutase Proteins 0.000 claims abstract description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 45
- 239000008101 lactose Substances 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 38
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- 239000008103 glucose Substances 0.000 claims description 22
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 108090000992 Transferases Proteins 0.000 claims description 5
- 102000004357 Transferases Human genes 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 102000004867 Hydro-Lyases Human genes 0.000 claims 2
- 108090001042 Hydro-Lyases Proteins 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 abstract description 24
- 235000021474 generally recognized As safe (food) Nutrition 0.000 abstract 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 13
- 101150066555 lacZ gene Proteins 0.000 description 12
- 108091008146 restriction endonucleases Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- LQEBEXMHBLQMDB-UHFFFAOYSA-N GDP-L-fucose Natural products OC1C(O)C(O)C(C)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C3=C(C(N=C(N)N3)=O)N=C2)O1 LQEBEXMHBLQMDB-UHFFFAOYSA-N 0.000 description 9
- LQEBEXMHBLQMDB-JGQUBWHWSA-N GDP-beta-L-fucose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C3=C(C(NC(N)=N3)=O)N=C2)O1 LQEBEXMHBLQMDB-JGQUBWHWSA-N 0.000 description 9
- 101000885514 Arabidopsis thaliana Putative fucosyltransferase-like protein Proteins 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 5
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 210000004251 human milk Anatomy 0.000 description 5
- 235000020256 human milk Nutrition 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 108020001019 DNA Primers Proteins 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- 101100022282 Escherichia coli O157:H7 manC2 gene Proteins 0.000 description 4
- 241000590002 Helicobacter pylori Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229940037467 helicobacter pylori Drugs 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 101150032120 manC gene Proteins 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 101100075927 Aspergillus aculeatus mndA gene Proteins 0.000 description 3
- 101001010029 Lactobacillus helveticus Putative phosphotransferase enzyme IIA component Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 101150088678 manB gene Proteins 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 101100280818 Escherichia coli (strain K12) fcl gene Proteins 0.000 description 2
- 238000012366 Fed-batch cultivation Methods 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000012365 batch cultivation Methods 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- SNFSYLYCDAVZGP-OLAZETNGSA-N 2'-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@H](O)[C@@H]1O SNFSYLYCDAVZGP-OLAZETNGSA-N 0.000 description 1
- AUNPEJDACLEKSC-ZAYDSPBTSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O AUNPEJDACLEKSC-ZAYDSPBTSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000006471 Fucosyltransferases Human genes 0.000 description 1
- 108010019236 Fucosyltransferases Proteins 0.000 description 1
- 101710119007 GDP-L-fucose synthase Proteins 0.000 description 1
- 238000004977 Hueckel calculation Methods 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 101100301239 Myxococcus xanthus recA1 gene Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000012511 carbohydrate analysis Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008131 children development Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 101150045500 galK gene Proteins 0.000 description 1
- 101150041954 galU gene Proteins 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 101150096208 gtaB gene Proteins 0.000 description 1
- 108010064833 guanylyltransferase Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 101150086432 lacA gene Proteins 0.000 description 1
- 101150001899 lacY gene Proteins 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000013365 molecular weight analysis method Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 101150012154 nupG gene Proteins 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 101150098466 rpsL gene Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01187—GDP-4-dehydro-D-rhamnose reductase (1.1.1.187)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01271—GDP-L-fucose synthase (1.1.1.271)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01065—3-Galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase (2.4.1.65), i.e. alpha-1-3 fucosyltransferase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01069—Galactoside 2-alpha-L-fucosyltransferase (2.4.1.69)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07013—Mannose-1-phosphate guanylyltransferase (2.7.7.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01047—GDP-mannose 4,6-dehydratase (4.2.1.47), i.e. GMD
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y504/00—Intramolecular transferases (5.4)
- C12Y504/02—Phosphotransferases (phosphomutases) (5.4.2)
- C12Y504/02008—Phosphomannomutase (5.4.2.8)
Definitions
- the present invention is ⁇ -1,2-fucosyltransferase, GDP-D-mannose-4,6-dehydratase (GDP-D-mannose-4,6-dehydratase , Gmd), to express GDP-L-fucose synthase (GDP-4-keto-6-deoxymannose-3,5-epimerase-4-reductase, WcaG) and lactose permease (LacY) Recombinant corynebacterium glutamiform transformed and transformed to overexpress phosphomannomutase (ManB) and mannose-1-phosphate guanylyl transferase (GTP-mannose-1-phosphate guanylyltransferase (ManC) C. glutamicum and a method for producing fucosylactose using the same.
- Human milk contains over 200 unique structures of human milk oligosaccharides (HMO) at significantly higher concentrations (5-15 g / L) than other mammalian milk.
- HMO human milk oligosaccharides
- HMO provides a variety of biological activities that positively affect infant development and health, such as prebiotic effects, pathogen infection prevention, immune system regulation, and brain development.
- fucosyllactose there is a method of extracting directly from breast milk and a method synthesized by chemical or enzymatic methods.
- the direct extraction method is a problem of limited milk supply and low productivity, and the chemical synthesis method has problems such as expensive substrate, low iso-selectivity and yield, and use of toxic organic solvent.
- the enzymatic synthesis method has a problem that GDP-L-fucose, which is used as a donor of fucose, is very expensive and the purification cost of fucosyltransferase is high.
- Escherichia coli since the cell membrane components of Escherichia coli can act as endotoxins, the cost of separation and purification is high in the production of 2'-fucosyllactose. Therefore, it is difficult to use Escherichia coli as a host cell for producing fucosyllactose, which is a food and pharmaceutical material.
- the present invention is transformed so that ⁇ -1,2-fucosyltransferase is expressed and GDP-D-mannose-4,6-dehydratase (GDP-D- transformed to express mannose-4,6-dehydratase, transformed to express GDP-L-fucose synthase, and to express lactose permease Recombinant Corynebacterium glutamimes, which are transformed and possess phosphomannomutase and GTP-mannose-1-phosphate guanylyltransferase Provide Cormebacterium glutamicum .
- the present inventors have previously patented the method for producing 2'-fucosyllactose using E. coli through Korean Patent Registration No. 10-1544184 (2015.08.21).
- the production of E. coli may be a problem due to various safety concerns of E. coli. Therefore, the present invention attempted to produce 2'-fucosyllactose through an alternative strain without food safety problems.
- Corynebacterium glutamicum ( Coynebacterium) as a host cell producing 2'- fucosyllactose glutamicum ), which is a strain recognized as GRAS (generally recognized as safe) unlike E. coli, which is not used in the past, does not produce endotoxin and is widely used for industrial production of amino acids and nucleic acids as food additives. It is becoming a strain. Therefore, Corynebacterium glutamicum can be said to be a suitable strain for the production of food and pharmaceutical materials, there is an advantage that can dispel the concern for consumers on the safety aspects.
- E. coli and Corynebacterium glutamicum differ in the genetic characteristics of the strain itself, a strategy different from that applied to E. coli should be used. It is basically the same to introduce foreign ⁇ -1,2-fucosyltransferase, whether E. coli or Corynebacterium glutamicum to produce 2'-fucosyllactose.
- Corynebacterium glutamicum additionally contains GDP-D-mannose-4,6-dehydratase (Gmd), GDP-L-fucose synth (GDP-L-fucose synthase, this enzyme is also called 'GDP-4-keto-6-deoxy-D-mannose-3,5-epimerase-4-reductase'), also abbreviated as 'WcaG' Genes encoding these enzymes, in particular called WcaG) and lactose permease (LacY).
- Gmd GDP-D-mannose-4,6-dehydratase
- GDP-L-fucose synthase this enzyme is also called 'GDP-4-keto-6-deoxy-D-mannose-3,5-epimerase-4-reductase'
- WcaG lactose permease
- Escherichia coli contains GDP-D-mannose-4,6-dehydratase (GDP), GDP-L-fucose synthase (GDP-L-fucose synthase). , WcaG) and lactose permease (LacY), but genes encoding, but because the Corynebacterium glutamicum strain does not have a gene encoding the enzymes, it is introduced from outside It should be expressed.
- the gene encoding ⁇ -1,2-fucosyltransferase may be derived from Helicobacter pylori , GDP-D-mannose-4. , 6-dehydratase (GDP-D-mannose-4,6-dehydratase, Gmd), GDP-L-fucose-synthase (WcaG) and lactose permease (The gene encoding lactose permease (LacY) is recommended to be derived from E. coli.
- the recombinant Corynebacterium glutamicum of the present invention is preferably transformed to overexpress the phosphomannomutase, GTP-mannose-1-phosphate guanyltransferase (GTP-mannose-1- It is recommended that the phosphate guanylyltransferase be transformed to overexpress.
- Corynebacterium glutamicum itself encodes genes encoding phosphomannomutase (ManB), GTP-mannose-1-phosphate guanylyltransferase (ManC). Since it can be retained and expressed, it is not necessary to introduce a gene encoding the enzyme, but it is necessary to overexpress the enzyme for mass production. Accordingly, in the present invention, it is desirable to transform Corynebacterium glutamicum to overexpress these two enzymes.
- lactose permease LacY
- LacY lactose permease
- the term 'expression' used in the present invention the expression of the gene derived from the outside introduced into the strain in order to artificially express the enzyme that the Corynebacterium glutamicum strain of the present invention can not express itself
- the term 'overexpression' means that the Corynebacterium glutamicum strain of the present invention has a gene encoding its own enzyme and can be expressed by itself, but its expression amount is for the purpose of mass production. In order to increase the artificially increased the amount of expression of the enzyme means overexpressed.
- Corynebacterium glutamicum C. glutamicum
- 2'- fucosyllactose a breast milk oligosaccharide
- the gene encoding the ⁇ -1,2-fucosyltransferase is preferably a fucT2 gene, more preferably wild type fucT2 It is preferred that the fucT2 gene has the nucleic acid sequence set forth in SEQ ID NO: 6 in which some bases of the gene (eg SEQ ID NO: 4) are modified.
- SEQ ID NO: 6 some bases of the gene
- the present invention provides a method for producing 2'-fucosyllactose, characterized in that the culture of the recombinant Corynebacterium glutamicum of the present invention in a medium to which lactose is added.
- the recombinant Corynebacterium glutamicum strain of the present invention it is possible to produce 2'-fucosyllactose in high concentration, high yield, high productivity.
- the medium further comprises glucose.
- glucose is added to the medium, the growth of the strain is promoted, and 2'-fucosyllactose can be produced with higher productivity.
- the method for producing 2'-fucosyllactose of the present invention is preferably fed-batch culture additionally supplying glucose or lactose. This is because continuous feeding of glucose or lactose through fed-batch cultivation can further increase cell growth and produce fucosylactose with high purity, high yield, and high productivity. Detailed local techniques related to fed-batch culture may also use known techniques in the art, and thus description thereof will be omitted.
- FIG. 1 illustrates a metabolic pathway introduced to the biosynthesis of Corynebacterium glutamicum GDP-L-fucose, and lactose in the Foucault chamber (C. glutamicum) strain.
- 2 is lacZ removed lac The introduction of operon ( lacYA ) In Corynebacterium glutamicum (C. glutamicum) It is a graph evaluating the effect on 2'-fucosyllactose production.
- 2a is Corynebacterium glutamicum (C.
- Figure 2b the culture result of the strain (control) was overexpressed only ManB, ManC, Gmd and WcaG is overexpressed and the ManB, ManC, Gmd and WcaG, add FucT2
- the culture result of the strain introduced (Comparative Example 1)
- Figure 2c is a culture result of the strain introduced the lac operon ( lacYA ) in which the ManB, ManC, Gmd, WcaG, FucT2 and lacZ gene is removed (Example 1) .
- Symbols in the graph are as follows: ⁇ : dry cell weight, ⁇ : glucose, ⁇ : lactose,: lactate, ⁇ : 2'-fucosyllactose.
- Figure 3 is a graph showing the results of batch culture using recombinant Corynebacterium glutamicum ( C. glutamicum ) pVBCL + pEGWT.
- Figure 3a is a batch batch culture results
- Figure 3b is a fermenter batch culture results.
- OD 600 optical density
- IPTG and lactose were added so that the final concentrations were 1.0 mM and 10 g / L (arrows), respectively.
- Symbols in the graph are as follows: ⁇ : dry cell weight, ⁇ : glucose, ⁇ : lactose,: lactate, ⁇ : 2'-fucosyllactose.
- Figure 4 is a batch culture of recombinant Corynebacterium glutamicum ( C. glutamicum ) was confirmed the production of 2'-fucosyllactose through LC-MS / MS analysis.
- Figure 4a is a graph showing the production of fucosyllactose through the molecular weight in the cation mode using MALDI-TOP MS
- Figure 4b is structural of the fucosyllactose using Tandem mass spectrometry (MS / MS) It is a graph confirming the composition.
- FIG. 5 is a graph showing the fed-batch culture results using recombinant Corynebacterium glutamicum ( C. glutamicum ) pVBCL + pEGWT. After 40 g / L glucose was consumed at the beginning, glucose was supplied by continuous feeding and IPTG and lactose were added simultaneously (large arrow). Symbols in the graph are as follows: ⁇ : dry cell weight, ⁇ : glucose, ⁇ : lactose,: lactate, ⁇ : 2'-fucosyllactose.
- FIG. 6 fucT2 from Helicobacter pylori ( H. pylori ) To increase the translation efficiency of the gene, fucT2 Codon optimization of the gene for Corynebacterium glutamicum ( C.glutamicum ) is shown.
- Figure 7 is codon optimized for Corynebacterium glutamicum (C.glutamicum) fucT2 It is a graph showing the effect of the introduction of the gene (CO fucT2 ) on the production of 2'- fucosyllactose .
- Figure 7a is recombinant Corynebacterium glutamicum (C. glutamicum) pVBCL + pEGWT in flask batch culture results with (CO), the optical density (OD 600) is reached to about 0.8, respectively to have a final concentration of IPTG and lactose 1.0 mM, 10 g / L (arrow) was added.
- Figure 7b is recombinant Corynebacterium glutamicum (C.
- Example 1 Recombinant strain and plasmid preparation
- Escherichia coli for the production of plasmid and production of 2'-fucosyllactose (2'-FL), respectively.
- coli was used as the TOP10 and Corynebacterium glutamicum (C. glutamicum) ATCC 13032.
- H. pylori (Helicobacter pylori) FucT2 by PCR using two DNA primers (F_inf_ Sac I_RBS_fucT2 and R_inf_ Sac I_fucT2) from genomic DNA of ATCC 700392 After amplifying the gene, pEGWT was constructed by treating restriction enzyme Sac I and inserting it into the pEGW plasmid treated with the same restriction enzyme.
- pGRG36 Tn7 insertion vector pSC101 replicon, Amp R pBHA Cloning vector, pUC replicon, Amp R pGlacYA pGRG36 + lacYA pBHA (CO fucT2 ) pBHA + CO fucT2 pEGW pEKEx2 + gmd-wcaG pVmBC pVWEx2 + manB + manC pEGWT pEGW + fucT2 pVBCL PVmBC + lacYA pEGWT (CO) pEGW + CO fucT2
- test tube containing 5 mL of BHI (Brain Heart Infusion) medium containing appropriate antibiotics (kanamycin 25 ⁇ g / mL, tetracycline 5 ⁇ g / mL) was used. The temperature was maintained at 30 ° C. and the stirring speed was 250 rpm. And incubated for 12 hours.
- BHI Brain Heart Infusion
- antibiotics kanamycin 25 ⁇ g / mL, tetracycline 5 ⁇ g / mL
- Batch cultivation consists of 100 mL or 1 L of minimal medium ((NH 4 ) 2 SO 4 20 g / L, urea 5 g / L, KH 2 PO 4 1 g / L, K 2 HPO 4 1 g / L, MgSO 4 0.25 g / L, MOPS 42 g / L, CaCl 2 10 mg / L, Biotin 0.2 mg / L, Protocatechuic acid 30 mg / L, FeSO 4 7H 2 0 10 mg / L, MnSO 4 H 2 O 10 mg / L In 500 mL of bioreactor (bioreactor, Kobiotech, Incheon, Korea) containing ZnSO 4 7H 2 O 1 mg / L, CuSO 4 0.2 mg / L, NiCl 2 6H 2 O 0.02 mg / L, pH7.0 It was performed at 30 °C.
- minimal medium ((NH 4 ) 2 SO 4 20 g / L, urea 5 g / L, KH 2 PO
- the stirring speed was maintained at 250 rpm for the flask and 1000 rpm for the bioreactor at 2 vvm.
- optical density OD 600
- IPTG isopropyl- ⁇ -D-thiogalactopyranoside
- lactose were added at a final concentration of 1.0 mM and 10 g / L, respectively.
- a fed-batch culture for high concentration cell culture consists of a 2.5 L bioreactor containing a 1.0 L minimal medium containing 40 g / L glucose and appropriate antibiotics (kanamycin 25 ⁇ g / mL, tetracycline 5 ⁇ g / mL). , Kobiotech, Incheon, Korea).
- a feeding solution containing 800 g / L of glucose was supplied by a continuous feeding method at a rate of 5.7 g / L / h.
- lactose was added to a final concentration of 1.0 mM, 10 g / L.
- Dry cell weight was determined by multiplying the optical density (OD) by a conversion factor of 0.3.
- Optical density (OD) was measured at an absorbance of 600 nm using a spectrophotometer (spectrophotometer, Ultrospec 2000, Amersham Pharmacia Biotech, USA) after appropriate dilution of the sample to adjust the optical density in the range between 0.1-0.5.
- Concentrations of 2'-fucosyllactose, lactose, lactate, glucose and acetic acid were determined by HPLC (high performance) equipped with 'Carbohydrate Analysis column (Rezex ROA-organic acid, Phenomenex, USA)' and 'refractive index' (RI) detectors. liquid chromatography) (Agilent 1100LC, USA). A column heated at 60 ° C. was applied to analyze 20 ⁇ l of culture medium diluted 10-fold. A 5 mM H 2 SO 4 solution at 0.6 mL / min flow rate was used as the mobile phase.
- lac operon on the chromosome of E. coli was removed to form E. coli without the activity of ⁇ -galactosidase and only the activity of the lactose transporter, and ⁇ -galactosidase ( ⁇ ).
- lacZ encoding -galactosidase) 2'-fucosyllactose was produced by introducing the lac operon ( lacYA ) from which the gene was removed, into the genome of E. coli (Korean Patent No. 10-1544184).
- lactose transporter was introduced into the strain and used to produce 2'- fucosyllactose .
- the production of 2'- fucosyllactose was performed by the lac operon ( lacYA ) from which the lacZ gene was removed. It was confirmed that the introduction is essential.
- lacZ removed lac The introduction of operon ( lacYA ) In Corynebacterium glutamicum (C. glutamicum) Assessment of the effect on 2'-fucosyllactose production Plasmid Final dry cell weight (g / L) Lactose Consumption a (g / L) Maximum 2'-fucosyllactose concentration a (mg / L) Yield (mole 2'-fucosyllactose / mole lactose) Productivity a (mg / L / h) pVBCpEGW 13.5 0.02 N.D. - - pVBCpEGWT 12.9 0.02 N.D. - - pVBCLpEGWT 13.4 0.78 246 0.22 5.0
- Figure 3 is a graph showing the batch culture results using recombinant Corynebacterium glutamicum ( C. glutamicum ) pVBCL + pEGWT
- Figure 3a is a flask batch culture results 3b is the result of the fermenter batch culture.
- Figure 4a is to confirm the production of fucosyllactose through the molecular weight analysis of the material contained in the culture medium using MALDI-TOP MS, Figure 4b using Tandem mass spectrometry (MS / MS) By structurally confirming that the peak of 511.134 m / z is 2'-fucosyllactose.
- Feeding solution was supplied at a rate of 5.7 g / L / h by using a continuous feeding method to maintain cell growth from the time when 40 g / L of glucose was initially added. .
- IPTG and lactose were added to induce the production of 2'-fucosyllactose.
- Figure 5 is a graph showing the fed-batch culture results using recombinant Corynebacterium glutamicum pVBCL + pEGWT.
- Codon optimized fucT2 A fed-batch culture in batch culture, in a fermentor flask to investigate the 2'Foucault room lactose fermentation production performance and features of a recombinant of Corynebacterium glutamicum (C. glutamicum) are constructed using the gene (CO fucT2) Each was carried out.
- IPTG and lactose were added at a final concentration of 1.0 mM and 10 g / L, respectively.
- 40 g / L of glucose was initially added.
- Feeding solution was supplied at a rate of 5.7 g / L / h using a continuous feeding method in order to maintain cell growth from the point at which all of them were consumed.
- IPTG and lactose were added to induce the production of 2'-fucosyllactose.
- Figure 7a is a graph showing the flask batch culture results using recombinant Corynebacterium glutamicum ( C. glutamicum ) pVBCL + pEGWT (CO)
- Figure 7b is a recombinant Cory Nebacterium glutamicum ( C. glutamicum ) is a graph showing the fermentation fed-batch culture results using pVBCL + pEGWT (CO).
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
유전자명 | 서열번호 |
manB | 서열번호 1 |
manC | 서열번호 2 |
gmd-wcaG | 서열번호 3 |
fucT2 | 서열번호 4 |
lacYA | 서열번호 5 |
COfucT2 | 서열번호 6 |
균주 | 관련된 특징 |
E. coli TOP10 | F-, mcrA Δ(mrr - hsdRMS- mcrBC) φ80lacZΔM15 lacX74 recA1 araD139Δ (ara-leu)7697 galU galK rpsL (StrR) endA1 nupG |
C. glutamicum | Wild-type strain, ATCC 13032 |
플라스미드 | 관련된 특징 |
pEKEx2 | KmR; C. glutamicum /E. coli shuttle vector for regulatedgene expression (P tac , lacIq , pBL1, oriVC.g., oriVE .c.) |
pVWEx2 | TcR; C. glutamicum /E. coli shuttle vector for regulatedgene expression (P tac , lacIq , pHM1519, oriVC .g., oriVE .c.) |
pGRG36 | Tn7 insertion vector, pSC101 replicon, AmpR |
pBHA | Cloning vector, pUC replicon, AmpR |
pGlacYA | pGRG36 + lacYA |
pBHA(COfucT2) | pBHA + COfucT2 |
pEGW | pEKEx2 + gmd-wcaG |
pVmBC | pVWEx2 + manB + manC |
pEGWT | pEGW + fucT2 |
pVBCL | PVmBC + lacYA |
pEGWT(CO) | pEGW + COfucT2 |
프라이머 이름 | 서열(5'→3') | 서열번호 |
F_KpnI-gmd | GGGGTACC AAGGAGATATACAATGTCAAAAGTCGCTCTCATCACC | 서열번호 7 |
R_SacI-wcaG | CGAGCTCTTACCCCCGAAAGCGGTCTTG | 서열번호 8 |
F_PstI-manB | AACTGCAG AAGGAGATATACAATGCGTACCCGTGAATCTGTCAC | 서열번호 9 |
R_BamHI-SpeI-XbaI-manB | CGGGATCCGGACTAGTGCTCTAGATTATGCGCGGATAATCCCTA | 서열번호 10 |
F_XbaI-manC | GCTCTAGA AAGGAGATATACAATGACTTTAACTGACAAC | 서열번호 11 |
R_SpeI-manC | GGACTAGTCTACTGATCAGACGAAAA | 서열번호 12 |
F_inf_AsiSI_lacYA | GTCCTTTTAACAGCGATCGCACCATCGAATGGCGCAAAACCTTTCG | 서열번호 13 |
R_inf_AsiSI_lacYA | GAGACGAAATACGCGATCGCGCTGTGGGTCAAAGAGGCATGATG | 서열번호 14 |
F_inf_SacI_RBS_fucT2 | GGGGGTAACTTAAGGAGCTC AAGGAGATATACAATGGCTTTTAAGGTGGTGCAAATTTGCG | 서열번호 15 |
R_inf_SacI_fucT2 | CGGCCAGTGAATTCGAGCTCTTAAGCGTTATACTTTTGGGATTTTACCTCAAAATG | 서열번호 16 |
F_SacI_RBS_COfucT2 | CGAGCTC AAGGAGATATACAATGG | 서열번호 17 |
R_SacI_COfucT2 | CGAGCTCTTATGCGTTATACTTCTG | 서열번호 18 |
플라스미드 | 최종 건조 세포 중량(g/L) | 락토오스 소모량a(g/L) | 최대 2'-푸코실락토오스 농도a(mg/L) | 수율(mole 2'-푸코실락토오스/mole 락토오스) | 생산성a (mg/L/h) |
pVBCpEGW | 13.5 | 0.02 | N.D. | - | - |
pVBCpEGWT | 12.9 | 0.02 | N.D. | - | - |
pVBCLpEGWT | 13.4 | 0.78 | 246 | 0.22 | 5.0 |
최종 건조 세포 중량(g/L) | 락토오스 소모량a(g/L) | 최대 2'-푸코실락토오스 농도a(mg/L) | 수율(mole 2'-푸코실락토오스/mole 락토오스) | 생산성a (mg/L/h) | |
플라스크 | 13.4 | 0.78 | 246 | 0.22 | 4.97 |
발효기 | 13.0 | 0.57 | 274 | 0.34 | 5.6 |
플라스미드 | 최종 건조 세포 중량(g/L) | 락토오스 소모량a(g/L) | 최대 2'-푸코실락토오스 농도a(g/L) | 수율(mole 2'-푸코실락토오스/mole 락토오스) | 생산성a (g/L/h) |
pVBCLpEGWT | 57.3 | 7.3 | 5.8 | 0.55 | 0.06 |
최종 건조 세포 중량(g/L) | 락토오스 소모량a(g/L) | 최대 2'-푸코실락토오스 농도a | 수율(mole 2'-푸코실락토오스/mole 락토오스) | 생산성a | |
회분식(플라스크) | 14.2 | 0.94 | 370 (mg/L) | 0.28 | 7.18 (mg/L/h) |
유가식(발효기) | 62.1 | 13.6 | 8.1 (g/L) | 0.42 | 0.07(g/L/h) |
Claims (7)
- α-1,2-푸코오스 전이효소 (α-1,2-fucosyltransferase)가 발현되도록 형질전환되고,GDP-D-만노오스-4,6-데하이드라타아제 (GDP-D-mannose-4,6-dehydratase)가 발현되도록 형질전환되며,GDP-L-푸코오스 신타아제 (GDP-L-fucose synthase)가 발현되도록 형질전환되고,락토오즈 퍼미아제 (lactose permease)가 발현되도록 형질전환되며,포스포만노뮤타아제 (Phosphomannomutase) 및 GTP-만노오스-1-포스페이트 구아닐트랜스퍼라아제 (GTP-mannose-1-phosphate guanylyltransferase)를 보유하고 있는 것을 특징으로 하는 재조합 코리네박테리움 글루타미쿰 (Corynebacterium glutamicum).
- 제1항에 있어서,상기 α-1,2-푸코오스 전이효소 (α-1,2-fucosyltransferase)는,fucT2 유전자로 암호화된 것을 특징으로 하는 재조합 코리네박테리움 글루타미쿰.
- 제2항에 있어서,상기 fucT2 유전자는,서열번호 6의 핵산서열로 구성된 것을 특징으로 하는 재조합 코리네박테리움 글루타미쿰.
- 제1항에 있어서,상기 재조합 코리네박테리움 글루타미쿰은,포스포만노뮤타아제 (Phosphomannomutase)가 과발현되도록 형질전환되고,GTP-만노오스-1-포스페이트 구아닐트랜스퍼라아제 (GTP-mannose-1-phosphate guanylyltransferase)가 과발현되도록 형질전환된 것을 특징으로 하는 재조합 코리네박테리움 글루타미쿰.
- 락토오스가 첨가된 배지에, 제1항의 재조합 코리네박테리움 글루타미쿰 (Corynebacterium glutamicum)을 배양하는 것을 특징으로 하는 2'-푸코실락토오스의 생산방법.
- 제5항에 있어서,상기 배지는,글루코오스를 더 포함하는 것을 특징으로 하는 2'-푸코실락토오스의 생산방법.
- 제6항에 있어서,상기 푸코실락토오스의 생산방법은,글루코오스 또는 락토오스를 추가로 공급하는 유가식 배양인 것을 특징으로 하는 2'-푸코실락토오스의 생산방법.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017560310A JP6650950B2 (ja) | 2016-04-25 | 2017-04-24 | コリネバクテリウムグルタミクムを用いた2’−フコシルラクトースの生産方法 |
CA3020682A CA3020682C (en) | 2016-04-25 | 2017-04-24 | Method of producing 2'-fucosyllactose using corynebacterium glutamicum |
US15/574,028 US10570399B2 (en) | 2016-04-25 | 2017-04-24 | Corynebacterium glutamicum for use in producing 2′-fucosyllactose |
CN201780001667.5A CN107849577B (zh) | 2016-04-25 | 2017-04-24 | 利用谷氨酸棒状杆菌的2’-岩藻糖基乳糖的生产方法 |
EP17789868.1A EP3450562B1 (en) | 2016-04-25 | 2017-04-24 | Method for producing 2'-fucosyllactose by using corynebacterium glutamicum |
AU2017256470A AU2017256470B2 (en) | 2016-04-25 | 2017-04-24 | Method for producing 2'-fucosyllactose by using Corynebacterium glutamicum |
US16/589,724 US10876122B2 (en) | 2016-04-25 | 2019-10-01 | Method of producing 2′-fucosyllactose using recombinant Corynebacterium glutamicum |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0050219 | 2016-04-25 | ||
KR1020160050219A KR101731263B1 (ko) | 2016-04-25 | 2016-04-25 | 코리네박테리움 글루타미쿰을 이용한 2'-푸코실락토오스의 생산방법 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/574,028 A-371-Of-International US10570399B2 (en) | 2016-04-25 | 2017-04-24 | Corynebacterium glutamicum for use in producing 2′-fucosyllactose |
US16/589,724 Division US10876122B2 (en) | 2016-04-25 | 2019-10-01 | Method of producing 2′-fucosyllactose using recombinant Corynebacterium glutamicum |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017188684A1 true WO2017188684A1 (ko) | 2017-11-02 |
Family
ID=58742961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/004340 WO2017188684A1 (ko) | 2016-04-25 | 2017-04-24 | 코리네박테리움 글루타미쿰을 이용한 2'-푸코실락토오스의 생산방법 |
Country Status (8)
Country | Link |
---|---|
US (2) | US10570399B2 (ko) |
EP (1) | EP3450562B1 (ko) |
JP (2) | JP6650950B2 (ko) |
KR (1) | KR101731263B1 (ko) |
CN (1) | CN107849577B (ko) |
AU (1) | AU2017256470B2 (ko) |
CA (1) | CA3020682C (ko) |
WO (1) | WO2017188684A1 (ko) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3613858A4 (en) * | 2017-04-21 | 2021-01-06 | Seoul National University R&DB Foundation | PROCESS FOR THE PRODUCTION OF 3'-FUCOSYLLACTOSE USING CORYNEBACTERIUM GLUTAMICUM |
JP2021514633A (ja) * | 2018-04-04 | 2021-06-17 | アドヴァンスド プロテイン テクノロジーズ コーポレーションAdvanced Protein Technologies Corp. | シュードペドバクターサルタンス由来フコース転移酵素を用いた2’−フコシルラクトースの生産方法 |
WO2021122708A1 (en) | 2019-12-17 | 2021-06-24 | Inbiose N.V. | Lactose converting alpha-1,2-fucosyltransferase enzymes |
KR102477273B1 (ko) * | 2021-11-24 | 2022-12-16 | (주)에이피테크놀로지 | 효소 처리를 통한 2'-푸코실락토오스의 생산성 증대 방법 |
KR20230065393A (ko) * | 2021-11-03 | 2023-05-12 | (주)에이피테크놀로지 | 배양 배지 조성 및 배양 방식 변화에 따른 2'-푸코실락토오스의 생산성 증대 방법 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190045079A (ko) | 2017-10-23 | 2019-05-02 | (주)에이피테크놀로지 | 2'-푸코실락토오스 또는 3-푸코실락토오스를 함유한 안약 또는 안구 건조 방지용 조성물 |
KR101972925B1 (ko) | 2018-09-05 | 2019-04-26 | (주)에이피테크놀로지 | 2'-푸코실락토오스를 함유하는 자극 완화용 화장료 조성물 |
CN109402158B (zh) * | 2018-09-14 | 2022-01-11 | 江苏大学 | 一种产岩藻糖基乳糖的重组表达质粒载体、代谢工程菌及生产方法 |
CN109735479B (zh) * | 2019-01-30 | 2022-04-01 | 光明乳业股份有限公司 | 一种合成2’-岩藻糖基乳糖的重组枯草芽孢杆菌及其构建方法与应用 |
KR102154256B1 (ko) * | 2019-07-30 | 2020-09-10 | 서울대학교산학협력단 | 코리네박테리움 글루타미쿰을 이용한 3'-푸코실락토오스의 생산방법 |
KR102268092B1 (ko) | 2019-09-02 | 2021-06-25 | 서울대학교산학협력단 | 코리네박테리움 글루타미쿰에 푸코실락토오스 수송체 도입과 gdp-l-푸코오스 생합성 경로의 최적화를 통한 2'-푸코실락토오스 생산 증대 |
US20240279696A1 (en) * | 2019-12-16 | 2024-08-22 | Kyowa Hakko Bio Co., Ltd. | Microorganism having modified lactose permease, and method for producing lactose-containing oligosaccharide |
CN111471637A (zh) * | 2020-05-08 | 2020-07-31 | 江苏华燕集团有限公司 | 2`-岩藻糖基乳糖高产菌株及其制备方法和用途 |
KR102416352B1 (ko) | 2020-05-29 | 2022-07-06 | 한국식품연구원 | 아밀로수크라아제를 발현하는 재조합 코리네박테리움 글루타미쿰 균주, 및 이의 제조방법 |
CN111549013A (zh) * | 2020-06-09 | 2020-08-18 | 中国科学院天津工业生物技术研究所 | 一种atp依赖的甘露糖激酶及其在岩藻基乳糖合成中的应用 |
CN112342176A (zh) * | 2020-10-15 | 2021-02-09 | 江南大学 | 产2’-岩藻糖基乳糖的基因工程菌及其应用 |
KR20220096752A (ko) * | 2020-12-31 | 2022-07-07 | 주식회사 삼양사 | 푸코오스 전이효소를 발현하는 재조합 미생물 및 이를 이용한 2’-푸코실락토오스 제조방법 |
EP4043572A1 (en) | 2021-02-11 | 2022-08-17 | GALAB Laboratories GmbH | Glycosyltransferase deficient corynebacterium for the production of fucosyllactose |
EP4043571A1 (en) | 2021-02-11 | 2022-08-17 | GALAB Laboratories GmbH | Genetically modified corynebacterium for the production of fucosyllactose |
KR102462125B1 (ko) | 2021-09-03 | 2022-11-03 | 국민대학교산학협력단 | 조효소 엔지니어링을 통한 모유올리고당의 생물학적 생산방법 |
CN115011535A (zh) * | 2022-05-10 | 2022-09-06 | 南通励成生物工程有限公司 | 一种以葡萄糖为碳源合成2’-岩藻糖基乳糖的菌株及其构建方法和应用 |
WO2024123084A1 (ko) * | 2022-12-06 | 2024-06-13 | (주)에이피테크놀로지 | 베타-갈락토시다아제가 발현되도록 형질전환된 재조합 코리네박테리움 글루타미쿰을 이용한 푸코실락토오스의 생산방법 |
WO2024128827A1 (ko) * | 2022-12-14 | 2024-06-20 | (주)에이피테크놀로지 | 코리네박테리움 글루타미쿰을 이용한 락토-n-푸코펜타오스의 생산 방법 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020062361A (ko) * | 1999-12-21 | 2002-07-25 | 교와 핫꼬 고교 가부시끼가이샤 | 개변된 α1,2-푸코오스 전이효소 유전자 및α1,2-푸코오스 전이효소와 푸코오스 함유 당질의 제조법 |
KR101544184B1 (ko) | 2014-12-19 | 2015-08-21 | 서울대학교산학협력단 | 2-푸코실락토오스 생산 변이 미생물 및 이를 이용한 2-푸코실락토오스의 제조방법 |
KR101648352B1 (ko) * | 2015-11-09 | 2016-08-16 | 서울대학교산학협력단 | 푸코실락토오스 생산용 재조합 대장균 및 이를 이용한 푸코실락토오스의 생산방법 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6875591B1 (en) * | 1999-08-10 | 2005-04-05 | Kyowa, Hakko Kogyo Co., Ltd. | Process for producing GDP-fucose |
EP1275714A1 (en) * | 2000-04-11 | 2003-01-15 | Kyowa Hakko Kogyo Co., Ltd. | Alpha 1,2-fucosyltransferase and process for producing fucose-containing complex carbohydrate |
WO2010115935A1 (en) | 2009-04-07 | 2010-10-14 | Glycom A/S | Synthesis of 2 ' -o-fucosyllactose |
CA2827313C (en) | 2011-02-16 | 2023-08-22 | Glycosyn LLC | Biosynthesis of human milk oligosaccharides in engineered bacteria |
CA2830025A1 (en) | 2011-03-18 | 2012-09-27 | Glycom A/S | Synthesis of new fucose-containing carbohydrate derivatives |
KR20120122098A (ko) | 2011-04-28 | 2012-11-07 | 주식회사 진켐 | 박테로이드 프라질리스 균주 유래 푸코실전이효소 |
CA2835986A1 (en) * | 2011-05-13 | 2012-11-22 | Glycom A/S | Method for generating human milk oligosaccharides (hmos) or precursors thereof |
ES2733307T3 (es) * | 2011-12-16 | 2019-11-28 | Inbiose Nv | Microorganismos mutantes para sintetizar ácido colánico, oligosacáridos manosilados y/o fucosilados |
EP2708147B1 (en) * | 2012-09-14 | 2020-03-11 | Abbott Laboratories | Methods for increasing brain functionality using 2-fucosyl-lactose |
US9944965B2 (en) * | 2012-12-20 | 2018-04-17 | The Board Of Trustees Of The University Of Illinois | Biosynthesis of oligosaccharides |
CN103667371B (zh) * | 2013-11-11 | 2016-03-16 | 天津大学 | 一种丹参素的生物生产方法 |
EP3461890A1 (en) * | 2014-03-31 | 2019-04-03 | Jennewein Biotechnologie GmbH | Total fermentation of oligosaccharides |
KR101718681B1 (ko) * | 2014-06-23 | 2017-03-22 | 서울대학교산학협력단 | 가용성 단백질 발현량 및 활성이 증대된 헬리코박터 파일로리 유래 α-1,3 푸코실 전달효소의 유전자와 단백질 및 α-1,3 푸코실올리고당 생산에의 응용 |
CN104531597B (zh) * | 2014-09-22 | 2017-09-15 | 江南大学 | 一株产l‑苯丙氨酸的重组谷氨酸棒状杆菌及其构建与应用 |
RU2746410C2 (ru) * | 2014-11-14 | 2021-04-13 | Инбиос Н.В. | Мутантные микроорганизмы, устойчивые к гибели под действием лактозы |
-
2016
- 2016-04-25 KR KR1020160050219A patent/KR101731263B1/ko active IP Right Grant
-
2017
- 2017-04-24 US US15/574,028 patent/US10570399B2/en active Active
- 2017-04-24 AU AU2017256470A patent/AU2017256470B2/en active Active
- 2017-04-24 EP EP17789868.1A patent/EP3450562B1/en active Active
- 2017-04-24 CN CN201780001667.5A patent/CN107849577B/zh active Active
- 2017-04-24 JP JP2017560310A patent/JP6650950B2/ja active Active
- 2017-04-24 CA CA3020682A patent/CA3020682C/en active Active
- 2017-04-24 WO PCT/KR2017/004340 patent/WO2017188684A1/ko active Application Filing
-
2019
- 2019-10-01 US US16/589,724 patent/US10876122B2/en active Active
- 2019-11-13 JP JP2019205182A patent/JP2020022506A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020062361A (ko) * | 1999-12-21 | 2002-07-25 | 교와 핫꼬 고교 가부시끼가이샤 | 개변된 α1,2-푸코오스 전이효소 유전자 및α1,2-푸코오스 전이효소와 푸코오스 함유 당질의 제조법 |
KR101544184B1 (ko) | 2014-12-19 | 2015-08-21 | 서울대학교산학협력단 | 2-푸코실락토오스 생산 변이 미생물 및 이를 이용한 2-푸코실락토오스의 제조방법 |
KR101648352B1 (ko) * | 2015-11-09 | 2016-08-16 | 서울대학교산학협력단 | 푸코실락토오스 생산용 재조합 대장균 및 이를 이용한 푸코실락토오스의 생산방법 |
Non-Patent Citations (2)
Title |
---|
CHIN ET AL.: "Enhanced Production of 2'-fucosyllactose in Engineered Escherichia Coli BL21star( DE 3) by Modulation of Lactose Metabolism and Fucosyltransferase", JOURNAL OF BIOTECHNOLOGY, vol. 210, 17 July 2015 (2015-07-17), pages 107 - 1 15, XP029261145 * |
CHIN ET AL.: "Metabolic Engineering of Corynebacterium Glutamicum to Produce GDP-L-fucose from Glucose and Mannose", BIOPROCESS AND BIOSYSTEMS ENGINEERING, vol. 36, no. 6, 13 February 2013 (2013-02-13), pages 749 - 756, XP035365329 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3613858A4 (en) * | 2017-04-21 | 2021-01-06 | Seoul National University R&DB Foundation | PROCESS FOR THE PRODUCTION OF 3'-FUCOSYLLACTOSE USING CORYNEBACTERIUM GLUTAMICUM |
US11512318B2 (en) | 2017-04-21 | 2022-11-29 | Seoul National University R&Db Foundation | Method for producing 3-fucosyllactose using Corynebacterium glutamicum |
JP2021514633A (ja) * | 2018-04-04 | 2021-06-17 | アドヴァンスド プロテイン テクノロジーズ コーポレーションAdvanced Protein Technologies Corp. | シュードペドバクターサルタンス由来フコース転移酵素を用いた2’−フコシルラクトースの生産方法 |
EP3736336A4 (en) * | 2018-04-04 | 2021-11-24 | Advanced Protein Technologies Corp. | METHOD FOR PRODUCING 2'-FUCOSYLLACTOSE BY USING FUCOSYL TRANSFERASE FROM PSEUDOPEDOBATER SALTANS |
JP7075494B2 (ja) | 2018-04-04 | 2022-05-25 | アドヴァンスド プロテイン テクノロジーズ コーポレーション | シュードペドバクターサルタンス由来フコース転移酵素を用いた2’-フコシルラクトースの生産方法 |
WO2021122708A1 (en) | 2019-12-17 | 2021-06-24 | Inbiose N.V. | Lactose converting alpha-1,2-fucosyltransferase enzymes |
KR20230065393A (ko) * | 2021-11-03 | 2023-05-12 | (주)에이피테크놀로지 | 배양 배지 조성 및 배양 방식 변화에 따른 2'-푸코실락토오스의 생산성 증대 방법 |
KR102577779B1 (ko) | 2021-11-03 | 2023-09-14 | (주)에이피테크놀로지 | 배양 배지 조성 및 배양 방식 변화에 따른 2'-푸코실락토오스의 생산성 증대 방법 |
KR102477273B1 (ko) * | 2021-11-24 | 2022-12-16 | (주)에이피테크놀로지 | 효소 처리를 통한 2'-푸코실락토오스의 생산성 증대 방법 |
US11753665B2 (en) | 2021-11-24 | 2023-09-12 | Advanced Protein Technologies Corp. | Method for improving productivity of 2′-fucosyllactose through enzymatic treatment |
Also Published As
Publication number | Publication date |
---|---|
KR101731263B1 (ko) | 2017-05-02 |
EP3450562C0 (en) | 2023-07-19 |
AU2017256470B2 (en) | 2021-01-28 |
US10570399B2 (en) | 2020-02-25 |
JP6650950B2 (ja) | 2020-02-19 |
CN107849577A (zh) | 2018-03-27 |
US20180298389A1 (en) | 2018-10-18 |
EP3450562A4 (en) | 2019-12-04 |
CN107849577B (zh) | 2021-11-26 |
EP3450562A1 (en) | 2019-03-06 |
CA3020682C (en) | 2021-08-10 |
JP2020022506A (ja) | 2020-02-13 |
EP3450562B1 (en) | 2023-07-19 |
US20200048640A1 (en) | 2020-02-13 |
CA3020682A1 (en) | 2017-11-02 |
JP2018515118A (ja) | 2018-06-14 |
US10876122B2 (en) | 2020-12-29 |
AU2017256470A1 (en) | 2018-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017188684A1 (ko) | 코리네박테리움 글루타미쿰을 이용한 2'-푸코실락토오스의 생산방법 | |
US12060593B2 (en) | Fucosyltransferases and their use in producing fucosylated oligosaccharides | |
KR102050522B1 (ko) | 코리네박테리움 글루타미쿰을 이용한 3'-푸코실락토오스의 생산방법 | |
KR102335067B1 (ko) | 올리고당 생산 | |
WO2016153300A1 (ko) | 2-푸코실락토오스 생산 변이 미생물 및 이를 이용한 2-푸코실락토오스의 제조방법 | |
CN111094325A (zh) | 用于制备人乳低聚糖的微生物 | |
CN114774343B (zh) | 一种生产2’-岩藻糖基乳糖的大肠杆菌工程菌株及应用 | |
WO2019194410A1 (ko) | 슈도페도박터 살탄스 유래 푸코오스 전이효소를 이용한 2'-푸코실락토오스의 생산방법 | |
EP3724344A2 (en) | Sialyltransferases and uses thereof | |
KR102154256B1 (ko) | 코리네박테리움 글루타미쿰을 이용한 3'-푸코실락토오스의 생산방법 | |
WO2018194411A1 (ko) | 코리네박테리움 글루타미쿰을 이용한 3'-푸코실락토오스의 생산방법 | |
WO2023096197A1 (ko) | 효소 처리를 통한 2'-푸코실락토오스의 생산성 증대 방법 | |
CN116426452A (zh) | 合成2’-岩藻糖基乳糖的重组大肠杆菌菌株及其应用 | |
CN116769808A (zh) | 一种专一生产2′-岩藻糖基乳糖的菌株及应用 | |
KR101794971B1 (ko) | α-1,3-푸코실락토오즈의 대량 생산 방법 | |
WO2023219437A1 (ko) | 코리네박테리움 글루타미쿰을 이용한 락토-n-테트라오스 및 락토-n-네오테트라오스의 생산 방법 | |
DK181497B1 (en) | ENHANCING FORMATION OF THE HMOS LNT AND/OR LNnT BY MODIFYING LACTOSE IMPORT IN THE CELL | |
KR101794972B1 (ko) | α-1,3-푸코실락토오즈의 대량 생산 방법 | |
CN118460581A (zh) | 构建稳定遗传的水杨苷生物合成的基因工程菌株的方法及其应用 | |
CN117015607A (zh) | 用于生产岩藻糖基乳糖的遗传修饰的棒状杆菌 | |
CN116802299A (zh) | 用于生产岩藻糖基乳糖的糖基转移酶缺陷型棒状杆菌 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2017560310 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15574028 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 3020682 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017256470 Country of ref document: AU Date of ref document: 20170424 Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17789868 Country of ref document: EP Kind code of ref document: A1 |